High-dose therapy is an effective standard treatment for multiple myeloma patients. Evidence
that intermediate-dose therapy improves survival is limited. At diagnosis, about 70% of …

… Ed è su questo punto che Federica Cavallo chiarisce con stimolante efficacia il porsi
inconciliabile di forti antinomie innescate dalle repentine trasformazioni territoriali apportate dal …

Using fluorescence in situ hybridization we investigated amplification of chromosome band
1q21 (Amp1q21) in more than 500 untreated patients with monoclonal gammopathy of …

A new SH2-containing sequence, WC, was isolated by screening cDNA libraries with SH2
representative DNA probes. The WC cDNA is predicted to encode overlapping proteins of …

Background This open-label, randomized, phase 3 study compared melphalan at a dose of
200 mg per square meter of body-surface area plus autologous stem-cell transplantation …

During the past decades, anticancer immunotherapy has evolved from a promising therapeutic
option to a robust clinical reality. Many immunotherapeutic regimens are now approved …

The initial analysis of the oral combination melphalan, prednisone, and thalidomide (MPT)
in newly diagnosed patients with myeloma showed significantly higher response rate and …

It is unknown whether zoledronic acid (ZA) at clinically relevant doses is active against
tumours not located in bone. Mice transgenic for the activated ErbB‐2 oncogene were treated …

Background Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is an aggressive
cancer with a median overall survival of less than 6 months. We aimed to assess the …

Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM)
but is associated with an increased risk of venous thromboembolism (VTE). This prospective, …